BAM
AMED

Belpointe Asset Management’s Amedisys AMED Stock Holding History

Belpointe Asset Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-633
Closed -$46.6K – 709
2023
Q1 		$46.6K Sell
633
-45
-7% -$3.89K ﹤0.01% 1742
2022
Q4 		$56.6K Buy
+678
New +$61.1K ﹤0.01% 1532

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Belpointe Asset Management's AMED Position: Q2 2023 in Review

Belpointe Asset Management sold out of Amedisys (AMED) in Q2 2023, closing a stake of 633 shares — an estimated $46.6K sold.

Belpointe Asset Management first reported a position in AMED in Q4 2022 and held it in 2 quarters. The position peaked at $56.6K in Q4 2022. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

  • Belpointe Asset Management reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 633 Amedisys shares in Q2 2023, an estimated $46.6K.
  • Belpointe Asset Management first reported a position in Amedisys in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Amedisys position peaked at $56.6K in Q4 2022.
  • 301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.